Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: A randomised, controlled, phase 3 trial

Paul E. Goss*, Ian E. Smith, Joyce O'Shaughnessy, Bent Ejlertsen, Manfred Kaufmann, Frances Boyle, Aman U. Buzdar, Pierre Fumoleau, William Gradishar, Miguel Martin, Beverly Moy, Martine Piccart-Gebhart, Kathleen I. Pritchard, Deborah Lindquist, Yanin Chavarri-Guerra, Gursel Aktan, Erica Rappold, Lisa S. Williams, Dianne M. Finkelstein

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

119 Scopus citations

Fingerprint

Dive into the research topics of 'Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: A randomised, controlled, phase 3 trial'. Together they form a unique fingerprint.

Medicine and Dentistry

INIS

Immunology and Microbiology

Pharmacology, Toxicology and Pharmaceutical Science